



MAYNE PHARMA APPOINTS NEW CHIEF FINANCIAL OFFICER

17 July 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces the appointment of Mr Griffin D. Buchanan as Chief Financial Officer (CFO) of the Company, effective 1 August 2026.

Mr Griffin D. Buchanan is a senior finance executive with extensive experience in global medical technology and healthcare. He joins Mayne Pharma from Establishment Labs (NASDAQ: ESTA), a global medical technology company focused on women's health, where he served as Vice President, Operational Finance, leading financial planning, analysis and operational performance across the business. His appointment brings directly relevant sector experience to Mayne Pharma at a time when Women's Health remains a core pillar of the Company's portfolio. Prior to Establishment Labs, Mr Buchanan spent over 19 years at Siemens Healthineers (SHL:DE), one of the world's leading medical technology companies, where he held a series of senior finance leadership roles. As VP of Finance (country, business line CFO) for its Enterprise Services business, he held P&L, balance sheet and cash flow accountability for a business generating approximately US\$1.4 billion in annual revenue.

Mr Buchanan holds an Executive MBA from Friedrich-Alexander-Universität Erlangen-Nürnberg and a Bachelor of Science, Business Administration, Information Technologies & Operations from the University of New Hampshire's Peter T. Paul College of Business and Economics.

Mr Aaron Gray, CEO of Mayne Pharma said *"We are delighted to welcome Griffin as Mayne Pharma's new CFO. Griffin's appointment strengthens our leadership team with a finance executive who understands the global medical technology and women's health markets first-hand. His experience optimising large, complex healthcare businesses aligns closely with Mayne Pharma's priorities, and I look forward to working with him on executing our business objectives."*

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board of Directors.

Email Alerts

To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit <https://www.maynepharma.com/investor-relations/email-alerts/>

Follow us on [LinkedIn](#)

Mayne Pharma Group Limited

ABN 76 115 832 963

[maynepharma.com](https://www.maynepharma.com)

1538 Main North Road, Salisbury South, SA 5106 Australia





About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

For personal use only